الفهرس 
Study of Certain Pharmaceutical Preparations Having Chondrogenic Activity for Treatment of Osteoarthritis
ContentsOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
Osteoarthritis (OA) is one of the most common joint related diseases that lead to joint degeneration. Local drug delivery directly into joint for treatment of OA has created a growing need for new injectable intra-articular materials that can be used as alternative for oral treatment. Intra-articular drug delivery systems are more preferable than orally administered ones for joint regeneration as they can overcome the low bioavailability and unwanted side effects of some orally administered joint regenerating or analgesic drugs, leading to drug localization atthe site of action.
Diacerein (DCN) is considered as a structural modifying OA drug that can specifically hinder interleukins-1b (IL-1b) in human monocytes which cause an important effect on the degeneration of cartilage.However,its market product (Diacerein® oral tablets) has many precautions and warnings. Formulation of sustained release intraarticular injectable systems for the delivery of DCN directly into the site of OA can overcome the unwanted effects of the peroral DCN.
Accordingly, our study aimed to formulate DCN as a sustained release injectable intra articular system to be injected at the site of OA